Which has better valuation and earnings, ORPH or IXI?

Open Orphan has higher revenue and earnings than IXICO. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Open Orphan £34.71M 0.00 N/A N/A N/A IXICO £7.28M 2.50 -£3.58M -£1.95 N/A

Is ORPH or IXI more profitable?

Open Orphan has a net margin of 0.00% compared to IXICO's net margin of -24.98%. Open Orphan's return on equity of 0.00% beat IXICO's return on equity. Company Net Margins Return on Equity Return on Assets Open Orphan N/A N/A N/A IXICO -24.98% -16.18% -10.40%

Which has preferable earnings & valuation, IXI or REDX?

IXICO has higher revenue and earnings than Redx Pharma. IXICO is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IXICO £7.28M 2.50 -£3.58M -£1.95 N/A Redx Pharma £4.20M 0.00 -£33.16M -£0.10 N/A

Is IXI or REDX more profitable?

Redx Pharma has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Redx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets IXICO -24.98% -16.18% -10.40% Redx Pharma N/A -180.80% -43.95%

Is POLB or IXI more profitable?

Poolbeg Pharma has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Poolbeg Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Poolbeg Pharma N/A -55.47% -21.33% IXICO -24.98% -16.18% -10.40%

Does the media refer more to POLB or IXI?

In the previous week, Poolbeg Pharma had 4 more articles in the media than IXICO. MarketBeat recorded 5 mentions for Poolbeg Pharma and 1 mentions for IXICO. IXICO's average media sentiment score of 1.60 beat Poolbeg Pharma's score of -0.01 indicating that IXICO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Poolbeg Pharma 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral IXICO 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate HVO or IXI?

hVIVO presently has a consensus target price of GBX 15, indicating a potential upside of 90.79%. Given hVIVO's stronger consensus rating and higher probable upside, analysts clearly believe hVIVO is more favorable than IXICO. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 IXICO 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, HVO or IXI?

hVIVO has higher revenue and earnings than IXICO. hVIVO is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio hVIVO £46.77M 1.16 £17.84M -£0.87 N/A IXICO £7.28M 2.50 -£3.58M -£1.95 N/A

Is HVO or IXI more profitable?

hVIVO has a net margin of -12.48% compared to IXICO's net margin of -24.98%. hVIVO's return on equity of -14.65% beat IXICO's return on equity. Company Net Margins Return on Equity Return on Assets hVIVO -12.48% -14.65% 11.97% IXICO -24.98% -16.18% -10.40%

IXICO (IXI) Competitors

GBX 8.34 -0.32 (-3.64%)

As of 06/19/2026 10:05 AM Eastern

Compare

IXI vs. ORPH, REDX, POLB, HVO, and HEMO

Should you buy IXICO stock or one of its competitors? MarketBeat compares IXICO with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IXICO include Open Orphan (ORPH), Redx Pharma (REDX), Poolbeg Pharma (POLB), hVIVO (HVO), and Hemogenyx Pharmaceuticals (HEMO). These companies are all part of the "biotechnology" industry.

How does IXICO compare to Open Orphan?

Open Orphan (LON:ORPH) and IXICO (LON:IXI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

In the previous week, IXICO had 1 more articles in the media than Open Orphan. MarketBeat recorded 1 mentions for IXICO and 0 mentions for Open Orphan. IXICO's average media sentiment score of 1.60 beat Open Orphan's score of 0.00 indicating that IXICO is being referred to more favorably in the news media.

Company	Overall Sentiment
Open Orphan	Neutral
IXICO	Very Positive

Open Orphan has a net margin of 0.00% compared to IXICO's net margin of -24.98%. Open Orphan's return on equity of 0.00% beat IXICO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Open Orphan	N/A	N/A	N/A
IXICO	-24.98%	-16.18%	-10.40%

Open Orphan has higher revenue and earnings than IXICO.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Open Orphan	£34.71M	0.00	N/A	N/A	N/A
IXICO	£7.28M	2.50	-£3.58M	-£1.95	N/A

13.0% of IXICO shares are owned by institutional investors. 7.2% of IXICO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

IXICO beats Open Orphan on 5 of the 9 factors compared between the two stocks.

How does IXICO compare to Redx Pharma?

IXICO (LON:IXI) and Redx Pharma (LON:REDX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

IXICO has higher revenue and earnings than Redx Pharma. IXICO is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IXICO	£7.28M	2.50	-£3.58M	-£1.95	N/A
Redx Pharma	£4.20M	0.00	-£33.16M	-£0.10	N/A

13.0% of IXICO shares are owned by institutional investors. Comparatively, 72.7% of Redx Pharma shares are owned by institutional investors. 7.2% of IXICO shares are owned by company insiders. Comparatively, 18.4% of Redx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, IXICO had 1 more articles in the media than Redx Pharma. MarketBeat recorded 1 mentions for IXICO and 0 mentions for Redx Pharma. IXICO's average media sentiment score of 1.60 beat Redx Pharma's score of 0.00 indicating that IXICO is being referred to more favorably in the media.

Company	Overall Sentiment
IXICO	Very Positive
Redx Pharma	Neutral

IXICO has a beta of 0.129, meaning that its stock price is 87% less volatile than the broader market. Comparatively, Redx Pharma has a beta of -0.53, meaning that its stock price is 153% less volatile than the broader market.

Redx Pharma has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Redx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IXICO	-24.98%	-16.18%	-10.40%
Redx Pharma	N/A	-180.80%	-43.95%

Summary

IXICO beats Redx Pharma on 8 of the 12 factors compared between the two stocks.

How does IXICO compare to Poolbeg Pharma?

Poolbeg Pharma (LON:POLB) and IXICO (LON:IXI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

In the previous week, Poolbeg Pharma had 4 more articles in the media than IXICO. MarketBeat recorded 5 mentions for Poolbeg Pharma and 1 mentions for IXICO. IXICO's average media sentiment score of 1.60 beat Poolbeg Pharma's score of -0.01 indicating that IXICO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Poolbeg Pharma	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
IXICO	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Poolbeg Pharma has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Poolbeg Pharma	N/A	-55.47%	-21.33%
IXICO	-24.98%	-16.18%	-10.40%

Poolbeg Pharma has a beta of 1.821, meaning that its stock price is 82% more volatile than the broader market. Comparatively, IXICO has a beta of 0.129, meaning that its stock price is 87% less volatile than the broader market.

IXICO has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.94	N/A
IXICO	£7.28M	2.50	-£3.58M	-£1.95	N/A

1.5% of Poolbeg Pharma shares are owned by institutional investors. Comparatively, 13.0% of IXICO shares are owned by institutional investors. 7.6% of Poolbeg Pharma shares are owned by company insiders. Comparatively, 7.2% of IXICO shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

IXICO beats Poolbeg Pharma on 7 of the 12 factors compared between the two stocks.

How does IXICO compare to hVIVO?

hVIVO (LON:HVO) and IXICO (LON:IXI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

11.8% of hVIVO shares are owned by institutional investors. Comparatively, 13.0% of IXICO shares are owned by institutional investors. 4.9% of hVIVO shares are owned by insiders. Comparatively, 7.2% of IXICO shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

hVIVO presently has a consensus target price of GBX 15, indicating a potential upside of 90.79%. Given hVIVO's stronger consensus rating and higher probable upside, analysts clearly believe hVIVO is more favorable than IXICO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
IXICO	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

hVIVO has a beta of 1.724, indicating that its stock price is 72% more volatile than the broader market. Comparatively, IXICO has a beta of 0.129, indicating that its stock price is 87% less volatile than the broader market.

hVIVO has higher revenue and earnings than IXICO. hVIVO is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£46.77M	1.16	£17.84M	-£0.87	N/A
IXICO	£7.28M	2.50	-£3.58M	-£1.95	N/A

In the previous week, IXICO had 1 more articles in the media than hVIVO. MarketBeat recorded 1 mentions for IXICO and 0 mentions for hVIVO. IXICO's average media sentiment score of 1.60 beat hVIVO's score of 0.00 indicating that IXICO is being referred to more favorably in the news media.

Company	Overall Sentiment
hVIVO	Neutral
IXICO	Very Positive

hVIVO has a net margin of -12.48% compared to IXICO's net margin of -24.98%. hVIVO's return on equity of -14.65% beat IXICO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-12.48%	-14.65%	11.97%
IXICO	-24.98%	-16.18%	-10.40%

Summary

hVIVO beats IXICO on 10 of the 16 factors compared between the two stocks.

How does IXICO compare to Hemogenyx Pharmaceuticals?

IXICO (LON:IXI) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

13.0% of IXICO shares are owned by institutional investors. Comparatively, 0.2% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 7.2% of IXICO shares are owned by insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, IXICO had 1 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 1 mentions for IXICO and 0 mentions for Hemogenyx Pharmaceuticals. IXICO's average media sentiment score of 1.60 beat Hemogenyx Pharmaceuticals' score of 0.00 indicating that IXICO is being referred to more favorably in the media.

Company	Overall Sentiment
IXICO	Very Positive
Hemogenyx Pharmaceuticals	Neutral

IXICO has a beta of 0.129, suggesting that its share price is 87% less volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.496, suggesting that its share price is 50% more volatile than the broader market.

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Hemogenyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IXICO	-24.98%	-16.18%	-10.40%
Hemogenyx Pharmaceuticals	N/A	-2,807.75%	-37.79%

Hemogenyx Pharmaceuticals has lower revenue, but higher earnings than IXICO. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IXICO	£7.28M	2.50	-£3.58M	-£1.95	N/A
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.89K	-£170.60	N/A

Summary

IXICO beats Hemogenyx Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Get IXICO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IXI vs. The Competition

Export

Metric	IXICO	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£18.86M	£381.56M	£6.43B	£2.88B
Dividend Yield	1.27%	3.86%	2.68%	6.15%
P/E Ratio	-4.27	3.12	24.75	366.85
Price / Sales	2.50	6,861.77	529.79	86,444.11
Price / Cash	2.25	13.13	45.07	27.85
Price / Book	0.43	92.26	10.80	8.01
Net Income	-£3.58M	-£96.07M	£3.57B	£5.89B
7 Day Performance	N/A	0.88%	0.72%	0.07%
1 Month Performance	0.42%	-0.66%	0.41%	0.93%
1 Year Performance	-25.31%	54.58%	29.34%	72.13%

IXICO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IXI IXICO	N/A	GBX 8.34 -3.6%	N/A	-25.3%	£18.86M	£7.28M	N/A	89	Positive News Gap Down
ORPH Open Orphan	N/A	N/A	N/A	N/A	£67.09M	£34.71M	N/A	179
REDX Redx Pharma	N/A	N/A	N/A	N/A	£58.35M	£4.20M	N/A	101	Gap Up High Trading Volume
POLB Poolbeg Pharma	N/A	GBX 7.88 +3.7%	N/A	+127.7%	£55.56M	N/A	N/A	12	Analyst Forecast Gap Up
HVO hVIVO	N/A	GBX 7.90 -4.2%	GBX 15 +89.8%	-22.9%	£54.40M	£46.77M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:IXI) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IXICO (IXI) Competitors